pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

The distribution of evidence level of drug-drug interaction between drug databases (N=382)

Lexicomp® Micromedex®

Level of evidence N (%) Excellent Good Fair

N (%) N (%) N (%)
Overall 382 (100.0) 6 (1.6) 17 (4.5) 359 (94.0)
Excellent 0 (0.0) 0 - 0 - 0 -
Good 71 (18.6) 2 (2.8) 0 (0.0) 69 (97.2)
Fair 311 (81.4) 4 (1.3) 17 (5.5) 292 (93.2)
With generic 41 (100.0) 2 (4.9) 2 (4.9) 37 (90.2)
Excellent 0 (0.0) 0 - 0 - 0 -
Good 13 (31.7) 1 (7.7) 0 (0.0) 12 (92.3)
Fair 28 (68.3) 1 (3.6) 2 (100.0) 25 (89.3)
Without generic 341 (100.0) 4 (1.2) 15 (4.4) 323 (94.7)
Excellent 0 (0.0) 0 - 0 - 0 -
Good 58 (17.0) 1 (1.7) 0 (0.0) 57 (98.3)
Fair 283 (83.0) 3 (1.1) 15 (5.3) 265 (93.6)

: The distribution of evidence level of DDI combinations was significantly different between tyrosine kinase inhibitors with generics and without generics in Lexicomp® database (p=0.008)

Korean J Clin Pharm 2020;30:44-50 https://doi.org/10.24304/kjcp.2020.30.1.44
© 2020 Korean J Clin Pharm